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The efﬁcacy of Bacillus Calmette-Guerin (BCG) vaccination in protection against pulmonary tuberculosis
(TB) is highly variable between populations. One possible explanation for this variability is increased
exposure of certain populations to non-tuberculous mycobacteria (NTM). This study used a murine
model to determine the effect that exposure to NTM after BCG vaccination had on the efﬁcacy of BCG
against aerosol Mycobacterium tuberculosis challenge. The effects of administering live Mycobacterium
avium (MA) by an oral route and killed MA by a systemic route on BCG-induced protection were eval-
uated. CD4þ and CD8þ T cell responses were proﬁled to deﬁne the immunological mechanisms un-
derlying any effect on BCG efﬁcacy. BCG efﬁcacy was enhanced by exposure to killed MA administered by
a systemic route; T helper 1 and T helper 17 responses were associated with increased protection. BCG
efﬁcacy was reduced by exposure to live MA administered by the oral route; T helper 2 cells were
associated with reduced protection. These ﬁndings demonstrate that exposure to NTM can induce
opposite effects on BCG efﬁcacy depending on route of exposure and viability of NTM. A reproducible
model of NTM exposure would be valuable in the evaluation of novel TB vaccine candidates.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.1. Introduction
Tuberculosis (TB) is caused by the bacterium Mycobacterium
tuberculosis (M. tb). It was estimated that in 2011, 12 million people
worldwide were suffering with TB disease and a further 8.7 million
people are infected each year [1]. The number of people living with
latent M. tb infection may be nearer 2 billion [2]. The incidence is
greatest in Asia (59% of TB cases) and Africa (26%) and the burden
of disease is particularly high in countries with high HIV
prevalence [1].ghan Institute of Medical
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bacterium bovis, is the only licensed vaccine for use against TB. BCG
induces CD4þ T helper type 1 and CD8þ T cell responses, which
play a protective role in the host’s immune response against M. tb
[3e5]. A meta-analysis of randomised controlled trials and casee
control studies that evaluated the efﬁcacy of BCG vaccination
against pulmonary TB showed efﬁcacy to vary between 0% and 80%
across these trials [6,7]. Forty one per cent of this variation could be
attributed to the geographical location where the trial was con-
ducted [6]. There are a number of theories to explain the variable
efﬁcacy of BCG vaccination against pulmonary TB. Animal studies
have shown genetically different strains of BCG have varying levels
of immunogenicity but the observation that the same vaccine
preparation confers signiﬁcantly different levels of protection in
different human populations implies that BCG strain difference is
probably not the only explanation [8e11]. Certain strains of M. tb
are more virulent than others and BCG vaccine efﬁcacy is impaired
inmice infectedwith these high-virulence strains [12,13]. Helminth
co-infection is associated with a reduction in the immunogenicity
of BCG vaccination in a mouse model [14e16]. Exposure to non-
tuberculous strains of mycobacteria (NTM) in the environment
may also contribute to the variability of BCG efﬁcacy [17,18]..
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NTM are ubiquitous in the environment, more prevalent in hot
climates than cold climates and are often associated with soil and
water supplies [20,21]. Around half of the species are capable of
causing infection in humans and animals although these infections
are generally opportunistic and often affect people with some de-
gree of immune suppression [19]. In populations where BCG is less
effective, there is a high level of exposure to NTM. This can be
demonstrated by comparing, on a population level, the reactivity to
puriﬁed protein derivatives (PPDs) of mycobacteria prior to BCG
vaccination. The frequency of responders and the magnitude of
interferon-g (IFNg) induced in response to PPDs of NTM species is
far greater in Malawian and South Indian populations, where the
efﬁcacy of BCG against pulmonary TB is 0%, compared to the UK,
where the efﬁcacy of BCG is 80% [22,23].
It has been shown in guinea pigs and mice that, like BCG, NTM
can induce protective immunity against M. tb infection, although
the level of protection is reported to be less than that conferred by
BCG [24e28]. Detailed analyses of the immune responses induced
by NTM infection are limited. An overview of reports indicates that
IFNg is commonly induced and production of TNFa, IL-1b and IL-6
has also been reported [5,29e31]. There are also reports that NTM
may induce mycobacteria-speciﬁc responses that are not protective
against M. tb infection; for example a T helper 2 type response and
the immune-modulatory cytokines IL-10 and TGFb [31e33].
Several studies in animal models have assessed the effect of
NTM exposure on the efﬁcacy conferred by subsequent BCG
vaccination against challenge with M. tb or M. bovis. Brandt et al.
published data showing that subcutaneous infection of mice with
a mix of Mycobacterium avium, Mycobacterium vaccae and Myco-
bacterium kansasii, which was subsequently cleared by antibiotic
treatment prior to BCG vaccination, reduced the level of protection
afforded againstM. tb aerosol challenge [27]. A similar reduction of
BCG efﬁcacy was seen in guinea pigs when M. avium strain
WAg206 was administered orally prior to BCG vaccination [24]. In
a study of BCG efﬁcacy in calves, no protection was conferred
against M. bovis challenge in animals with PPD sensitivity prior to
BCG vaccination [34]. This PPD sensitivity was attributed to natural
exposure to NTM before recruitment of the calves to the study. In
contrast to these studies, there are others that fail to show a
reduction in BCG efﬁcacy after exposure to NTM, highlighting the
variability and inconsistency of these models of NTM exposure
[25,26,35e38].
To understand the effect of NTM exposure in populations where
BCG fails to protect against pulmonary TB, we set out to model the
pattern of NTM exposure that is likely to occur. Despite the variable
efﬁcacy of BCG against pulmonary TB, vaccination confers a high
level of protection against childhood forms of severe TB (81%) and
World Health Authority guidance is that in TB-endemic populations
BCG should be administered at, or as soon after, birth as possible
therefore exposure to NTM occurs after BCG vaccination [7,19]. The
route by which people are exposed to NTM is unknown. Exposure
via the oral route in drinking water is a probable route, as is sys-
temic exposure. This study evaluated two models of NTM exposure
in mice previously vaccinated with BCG. The effect of NTM expo-
sure on BCG vaccine efﬁcacy was assessed by aerosol M. tb chal-
lenge and CD4þ and CD8þ T cell responses were proﬁled. We ﬁrst
modelled exposure to killed M. avium via the systemic route and
found BCG efﬁcacy was enhanced by this exposure. Flaherty et al.
have previously published a model of oral exposure to M. avium
after BCG vaccination and reported that exposure reduced the ef-
ﬁcacy of BCG against M. tb challenge [39]. We replicated Flaherty’s
model to compare the immune responses induced in a model that
compromises vaccine efﬁcacy to the responses induced in a model
that enhances vaccine efﬁcacy with the view to determine theimmunological mechanisms behind these differential effects on
BCG-induced immunity.
2. Materials and methods
2.1. Ethics statement
Animal procedures were performed in accordance with the UK
Animals (Scientiﬁc procedures) Act 1986 and were approved by the
University of Oxford Animal Care and Ethical Review Committee
(PPL 30/2414 and 30/2889).
2.2. Mycobacteria
BCG Pasteur (a kind donation from Dr A Rawkins) was grown in
Middlebrook 7H9 media (with 10% ADC supplement and 0.05%
Tween 80) at 37 C to mid-log phase, aliquoted and frozen in PBS
at 80 C. M. avium (MA) strain 724, strain 2-151 (both a kind
donation from Prof. I Orme) and MA strain 104 (a kind donation
from Prof. A Cooper) were grown in supplemented Middlebrook
7H9 media to mid-log phase and then plated on Middlebrook 7H10
plates (with 10% oleic acid-albumen-dextrose-catalase (OADC)
enrichment and 0.05% glycerol) for 2e3 weeks at 30 C. Smooth-
transparent and rough colonies were picked and suspended in
7H9 media, then incubated in a rotating incubator at 30 C over-
night to reduce clumping before freezing in PBS at 80 C. MA 724
was chosen based on well documented use in NTM exposure
models and it’s ability to cause a persistent infection in mice,
suggesting a degree of pathogenicity [25,36]. MA 104was the strain
used by Flaherty et al. in the published study we replicated [39].
This strainwas originally isolated from an AIDS patient and causes a
persistent infection in mice [40]. M. tb Erdmann KO1 was supplied
by the US Food and Drug Administration (FDA) or BEI Resources
(Manassas Virginia, USA).
2.3. Mice and immunisations
Female C57BL/6 J mice were from Harlan Laboratories, UK. An-
imals were ordered at six weeks of age. Ex-breeders and nine week
old mice were used as naïve controls in aerosol challenge experi-
ments. Groups of animals were kept in a speciﬁc pathogen free
facility within individually ventilated cages.
Frozen aliquots of bacteria were thawed and sonicated. Where
MAwas to be given heat-killed, the aliquots were placed in a water
bath at 80 C for 25 min. Bacteria were then diluted to the required
concentration in sterile PBS before administration. 100 ml of BCG in
PBS was injected subcutaneously (SC) at the base of the tail using a
U-100 29G syringe. 1  105 CFU was administered. 100 ml of MA
724 or 2-151 for intraperitoneal injection (IP) was suspended in
PBS and administered with a U-100 29G syringe in the right or left
side of the peritoneal cavity. In the IP exposure model 1  108 CFU
of killed MA strain 2-151 or 724 were administered. In the model
of oral exposure mice received 100 ml of live MA 104 suspended in
PBS via a dosing cannula inserted directly in to the stomach.
1  102 CFU was administered. Mice were restrained but not
anaesthetised for these procedures (Figure 1(A): Experiment plan
of the IP exposure model; Figure 4(A): Experiment plan of the oral
exposure model).
2.4. M. tb aerosol challenge
Mice were transferred to a containment level III (CL3) suite and
loaded into nose-only restrainers. Restrainers were inserted into an
exposure chamber inside a CL3 isolator. M. tbwas diluted in sterile
PBS and put in to a collision nebuliser. Dose escalation studies were
Figure 1. Cellular responses in BCG vaccinated mice that were or were not sensitised with MA 724 IP after BCG Responses were assayed at the 12 month time point; 4 weeks after
the last dose of MA 724. Cells from inguinal lymph nodes (LN) and spleens were stimulated with PPD-T. (A) Experiment plan (B and C) IFNg, TNFa and IL-2 production from CD4þ or
CD8þ T cells in the LN, (D) IL-17 production from CD4þ T cells in the LN and spleen, (E) IL-4 production from CD4þ T cells in the LN and spleen, (F) expression of CD25, FoxP3 and
CD39 on CD4þ T cells from the LN and spleen, (G) IL-10 production from CD4þ T cells in the LN and spleen. B ¼ BCG vaccinated only, BM ¼ BCG vaccinated mice which received MA
724. Results are expressed as a percentage of the CD4þ or CD8þ T cell population and are stimulation speciﬁc; media only control well values are subtracted. Each data point
represents one mouse and the median is displayed, n ¼ 5. The ManneWhitney U test was used to determine statistical signiﬁcance and is shownwhere differences were signiﬁcant.
Subcutaneous (Sub Cut.), Intraperitoneal (IP), M. avium (MA), Colony Forming Units (CFU), Day 0 (D0), Regulatory T cells (Tregs).
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deliver 100 CFU to each mouse in a 10 min period of nebuliser
activity followed by a ﬁve minute purge cycle with clean air. The
Biaera aeroMP controller monitored the airﬂow and pressure in the
apparatus. After exposure, mice were removed from the restrainers
and housed in CL3 containment cages. For quantiﬁcation of CFU in
M. tb infected lungs or spleens the organs were homogenised in
1 ml of PBS using the Precellys24 then plated on enriched Mid-
dlebrook 7H10 plates. After four weeks of incubation at 37 C col-
onies were counted. Lungs from three naïve mice were taken24 h after challenge to determine the dose ofM. tb administered in
the challenge. Vaccine efﬁcacy was determined from CFU quanti-
ﬁcation on lung and spleen homogenates taken 35 days after
challenge. In the model of oral exposure the burden of MA 104 CFU
in the lungs and spleen was determined by also plating homoge-
nates on Middlebrook 7H10 plates supplemented with 2 mg/ml
Clarithromycin to exclude MA growth. There was no difference in
the number of CFU between plates that contained antibiotic and
those that did not, therefore we concluded there was no growth of
MA 104 in the lungs or spleens of these mice.
Figure 2. Burden of M. tb CFU in the lungs and spleens 35 days after challenge Groups included naïve, BCG vaccinated (BCG) and BCG followed by MA 724 IP exposure (BCG þ MA
IP). Data are Log (10) of the colony forming unit (CFU) count of the whole organ. Each data point represents one mouse and the mean is displayed. A One-way ANOVA with
Bonferroni post test was used to determine statistical signiﬁcance; the p value for each comparison is displayed.
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Mouse spleens and lymph nodes were mechanically homoge-
nised in PBS, passed through a 70 mm cell strainer and erythrocytes
in the spleens were removed by re-suspension of cells in ACK lysis
buffer for ﬁve minutes. The reactionwas stopped by PBS. Cells were
centrifuged and resuspended in complete MEM (10% Foetal Calf
Serum, Pen/Strep and L-glutamine). Lungs were perfused before
dissection by injecting roughly 2 ml of sterile PBS into the heart.
Lungs were then dissected into PBS, diced into 1 mm pieces and
suspended in 5 ml of RPMI with 700 mg/ml collagenase and 30 mg/
ml DNAse (Sigma) for 30 min at 37 C. The reaction was stopped by
adding complete MEM, then the suspension was passed through a
70 mm sieve and mashed with a 5 ml syringe. Samples were
centrifuged and erythrocytes lysed with ACK lysis buffer. Cells were
centrifuged and resuspended in complete MEM.
For ﬂow cytometry, cells were incubated for six hours at 37 C in
the presence of PPD fromM. tb (PPD-T) at 10 mg/ml. After two hours,
0.22 ml of GolgiPlug (Brefeldin A) was added. Following incubation,
cells were stored at 4 C overnight.
2.6. Multi-parameter ﬂow cytometry
Cells were centrifuged, washed with PBS and then stained with
10 ml of live/dead ﬁxable stain diluted in PBS at the required
concentration for 10 min. All incubations in this protocol were on
ice and in the dark. Cell surface speciﬁc antibodies and FC block
(anti CD16/32) were diluted in PBS with 2% FBS (PBS-FBS). Surface
antibodies used in this study were B220 AF700 (clone RA3-6B2),
B220 PE-Texas red (clone RA3-6B2), CD3 PerCP-Cy5.5 (clone 145-
2c11), CD3 AF700 (clone 17A2), CD8a APC-ef780 (clone 53-6.7),
CD4 eFluor 650NC (clone GK1.5), CD44 AF700 (clone IM7), CD25
APC (clone PC61.5) and CD39 PE-Cy7 (clone 24DMS1). The cocktail
of surface antibodies was added to the live/dead stain and incu-
bated for 30 min. If cells were to be stained for intracellular
markers they were then washed in PBS-FBS and permeabilised by
incubation with Cytoﬁx/Cytoperm for 10 min. Cells were washedin PermWash and then incubated for 30 min with an intracellular
staining cocktail and Fc block diluted in PermWash. Intracellular
antibodies used in this study were IFNg Brilliant Violet 421 (clone
XMG1.2), IL-2 PE-Cy7 (clone JES6-5H4), IL-17a PerCP-Cy5.5 (clone
eBio17B7), TNFa FITC (clone MP6-XT22), IL-4 PE (clone 11B11), IL-
10 APC (clone JES5-16E3) and FoxP3 PE (clone FJK-16S). Cells were
ﬁnally resuspended in PBS-FBS for analysis. For M. tb infected
samples the protocol for cell staining was followed as above but at
CL3 containment. After the ﬁnal stage of staining the cells were
ﬁxed in PBS-FBS with 4% paraformaldehyde for 30 min. The
samples were then washed and resuspended in PBS-FBS then
transferred to a sterile 96 well U-bottom plate and removed from
CL3. Samples were run on a BD LSRII cytometer linked to Facs Diva
software and analysed with Flow Jo v8.8.7 and 9 (Tree Star Inc.). An
example of typical gating strategies is shown in Supplementary
Figure 1. For gating of cytokines the media control sample was
used to determine where the negative population fell. For CD44 a
preliminary experiment with ﬂuorescence minus one (FMO) was
performed to determine the level of marker expression. For some
experiments SPICE was used to display complicated data
comparisons.
2.7. Statistics
All data were graphed and analysed with Prism v5.0 (GraphPad
Software). Flow cytometry data are presented as an antigen-
speciﬁc response by subtracting media-only control values from
the antigen-speciﬁc value prior to analysis. These data were non-
parametric therefore the median value was calculated and signiﬁ-
cance between groups tested with the ManneWhitney U test.
Where comparison of multiple groups was made the One-way
ANOVA KruskaleWallis with Dunns post-test was applied. CFU
Log(10)data was tested for normal distribution using a D’Agostino
and Pearson omnibus normality test. The mean was calculated for
these samples and signiﬁcance between groups tested with a one-
way analysis of variance and Bonferroni post-test. Differences were
considered statistically signiﬁcant if p < 0.05.
Figure 3. Cellular response to M. tb infection 13 days after challenge Thirteen and sixteen days after M. tb challenge cells were isolated from lungs and pulmonary LN (LN) of naïve
mice, BCG-vaccinated mice (BCG) and mice vaccinated with BCG followed by MA 724 IP exposure (BM IP). Cells were stimulated with PPD-T and then stained for analysis by ﬂow
cytometry. (A) CD44 þ CD4þ T cells in the lung, (B) IFNg, TNFa and IL-2 production from CD4þ T cells in the lung, (C) CD44 þ CD8þ T cells in the lung, (D) IFNg, TNFa and IL-2
production from CD8þ T cells in the LN, (E) IL-17 þ CD4þ T cells in the lung and LN, (F) IL-4þ CD4þ T cells in the lung and LN, (G) IL-10 þ CD4þ T cells in the lung and LN, (H)
expression of CD25, FoxP3 and CD39 on CD4þ T cells from the lung and LN. Cytokine responses are antigen-speciﬁc; media control values are subtracted. Regulatory T cell (Treg)
frequency is not antigen-speciﬁc. Each data point represents one mouse and the median is displayed. The One-way ANOVA KruskaleWallis with Dunns post test was used to
determine statistical signiﬁcance; the p value is displayed where signiﬁcance was calculated.
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3.1. Exposure to killed MA IP after BCG vaccination increases the
magnitude of Th1 and CD8þ T cells
We set out to model human NTM exposure in order to assess it’s
effect on the immune response induced by BCG. We reasoned that
human exposure is likely to be repeated exposure to NTM at sys-
temic surfaces; such exposures do not generally cause pathological
infections in immunocompetent people. Micewere vaccinatedwith
BCG then given MA intraperitoneally (IP) once a month for 6
months. Mice are susceptible to pathological infection from this
strain of MA therefore MA was administered killed to avoid the
induction of a pathological infection. From a previous experiment
we knew that giving repeated doses of killed MA to BCG vaccinated
mice produced a stronger immune response than a single dose of
killed MA did (Supplementary Figure 2). An aerosolM. tb challenge
was conducted to assess the effect of MA exposure on the protec-
tion conferred by BCG vaccination. Immune responses were char-
acterised prior to M. tb challenge and 13 and 16 days after
challenge. The experiment plan is summarised in (Figure 1(A)).
Prior to challenge, in the inguinal lymph node (iLN) of mice that
received BCG alone PPD-T speciﬁc IFNgþ CD4þ T cells and TNFaþ
CD4þ T cells were recorded at a frequency of 0.03% and 0.05%
respectively (Figure 1(B)). Exposure to 6 doses of killed MA 724after BCG vaccination induced IFNgþ and TNFaþ PPD-speciﬁc
CD4þ T cells at 0.2% as well as IL-2þ CD4þ T cells at 0.1%. These
responses were greater compared to the BCG alone mice, however
the difference was not statistically signiﬁcant. The Th1 response
was more polyfunctional after exposure to MA; with greater pro-
portions of PPD-T speciﬁc CD4þ T cells secreting IFNg, TNFa and IL-
2, and CD4þ T cells secreting both IFNg and TNFa compared to the
BCG alone group (Supplementary Figure 3 ). No PPD-T speciﬁc
CD8þ T cell responses were detected in mice vaccinated with BCG
alone whereas a PPD-T speciﬁc IFNgþ CD8þ T cell response was
detected in MA-exposed group (Figure 1(C)). Similar frequencies of
IL-17 þ CD4þ T cells were detected between the groups in the iLN
(Figure 1(D)). IL-17 þ CD4þ T cells were recorded in the spleen of
the MA-exposed group whereas the median frequency was 0% in
the BCG alone group. In the MA-exposed group the frequency of IL-
4þ CD4þ T cells in the iLN and spleen were 0.04% and 0.02%
respectively, in the BCG alone group it was 0% in both organs
(Figure 1(E)). The frequency of regulatory Tcells (Tregs) in the iLN of
the MA-exposed group was 10% and in the BCG alone group 19%,
this difference was not statistically signiﬁcant (Figure 1(F)). The
frequency of Tregs in the spleen of both groups was comparable.
The median frequency of PPD-T speciﬁc IL-10 þ CD4þ T cells was
0.01% in the iLN of the MA-exposed group and 0.09% in the BCG
alone group; this difference was signiﬁcant (p ¼ 0.02; Figure 1(G)).
IL-10 responses in the spleen were very low in both groups.
Figure 4. Responses induced by oral exposure to live MA 104 after BCG vaccination (A) Experimental plan; mice were orally exposed to live MA 104 8 times at 2 week intervals after
BCG vaccination (BM) or left un-manipulated after BCG (B) and then challenged with M. tb. Immune responses were recorded at week 28, six weeks after the last dose of MA in the
exposed group and directly before challenge with M. tb. Cells from mesenteric lymph nodes (LN) and spleens were stimulated with PPD-T then stained for analysis by ﬂow
cytometry. (B and C) IFNg, TNFa and IL-2 production from CD4þ and CD8þ T cells in the spleen, (D) IL-4þ CD4þ T cells in the LN and spleen, (E) IL-10 þ CD4þ T cells in the LN and
spleen, (F) expression of CD25, FoxP3 and CD39 on CD4þ T cells from the LN and spleen. Cytokine responses are antigen-speciﬁc; media control values are subtracted. Regulatory T
cell (Treg) frequency is not antigen-speciﬁc. Each data point represents one mouse and the median is displayed. The ManneWhitney U test was used to test for statistical sig-
niﬁcance and is shown where differences were signiﬁcant. Subcutaneous (Sub Cut.), M. avium (MA), Colony Forming Units (CFU), Day 0 (D0), Regulatory T cells (Tregs), Intracellular
staining (ICS).
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protection against M. tb challenge
Thirty-ﬁve days after aerosol M. tb challenge, the group
receiving MA 724 after BCG had a signiﬁcantly lower CFU burden inthe lungs compared to the BCG alone group (p ¼ 0.017 lungs)
(Figure 2). The mean CFU count in the spleen of the group that
received MA 724 after BCG was lower compared to the group that
received BCG alone but this difference was not signiﬁcant. The
mean Log(10) CFU count in the naïve group was 6.37 lung; 5.31
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group that received MA 724 after BCG 5.54 lung; 4.1 spleen. Both
the BCG alone group and the group that received MA 724 after BCG
had a signiﬁcantly lower CFU burden in the lungs and spleen
compared to naïvemice (p¼ 0.0001 lungs, p¼<0.0001 spleen BCG
alone; p ¼ 0.0002 lungs, p ¼ <0.0001 spleen BCG þ MA).
3.3. Exposure to killed MA IP after BCG vaccination enhances Th1,
Th17 and CD8þ T cell responses in the lung during M. tb infection
Thirteen and 16 days after challenge with M. tb, the cellular
immune responses in the lungs, pulmonary lymph nodes (pLN) and
spleens were assayed. Day 16 data were similar to day 13 data, so
only day 13 data are presented. CD44 expression was used as a
marker for CD4þ and CD8þ T cell activation. Thirteen days after
M. tb challenge, there were signiﬁcantly greater frequencies of
activated CD4þ T cells in the lungs of the BCG alone and the MA-
exposed groups compared to naïve mice (p < 0.05B þ M and BCG
alone; Figure 3(A)). The same was also seen in the pulmonary LN
(pLN) and the spleen (p < 0.05B þ M and BCG alone pLN;
p < 0.05B þM and BCG alone spleen; data not shown). The median
frequency of IFNgþ, TNFaþ and IL-2þ CD4þ T cells in the lungs of
the MA-exposed group was 1e1.5%. In the BCG alone group the
median frequency of IFNgþ CD4þ Tcells was 0.2% and TNFaþ CD4þ
T cells was 0.8%. This was a lower frequency compared to the MA-
exposed group although not statistically signiﬁcant (Figure 3(B)).
NoTh1 responsewas detected in the lungs of the naïve group at day
13 or day 16.
The frequencies of activated CD8þ T cells were signiﬁcantly
higher in the lungs of the BCG alone group compared to naïve mice
(p < 0.05 BCG alone lungs; Figure 3(C)). Frequencies of activated
CD8þ T cells were signiﬁcantly higher in the pLN of the MA-
exposed group compared to naïve mice (p < 0.05B þ M pLN; data
not shown). In the pLN at day 13 the frequency of IFNgþ CD8þ T
cells in the MA-exposed group was signiﬁcantly higher than in the
BCG alone group (0.2% compared to 0.03%, p < 0.05; Figure 3(D)).
No IFNgþ CD8þ T cells were detected in the pLN of naïve mice.
Frequencies of TNFaþ and IL-2þ CD8þ T cells in the pLN were low
in all groups.
IL-17 þ CD4þ T cells were detected 13 days afterM. tb challenge
in the lung of theMA-exposed group but not the BCG alone or naïve
groups; the median frequency was 1.5% (Figure 3(E)). IL-4þ CD4þ T
cells were also detected in the lungs of the MA-exposed group but
not the BCG alone or naïve groups; the median frequency was 0.3%
(Figure 3(F)). A low level of IL-10 þ CD4þ T cells were detected in
the lungs and pLN of the MA-exposed group and the BCG alone
group; 0.05% and 0.03% respectively (Figure 3(G)). Frequencies of
regulatory T cells in the lungs of all groups were around 1%. The
frequency in the pLN of the MA-exposed group was 6%, the BCG
alone group was 4% and the naïve group 3%; these differences were
not statistically signiﬁcant.
3.4. Exposure to live MA orally after BCG vaccination enhances Treg
frequencies in the mesenteric lymph nodes
We replicated a previously published model where live MA is
administered orally after BCG vaccination [39]. Repeated doses of
live MA strain 104 (MA 104) were administered to mice at a low
dose of 100 CFU to induce a sub-clinical infection. Analysis of CD4þ
and CD8þ T cell responses were performed before and after chal-
lenge with M. tb: the model is represented in Figure 4(A).
After eight doses of live MA 104, the frequencies of PPD-T spe-
ciﬁc IFNgþ and TNFaþ CD4þ T cells in the spleen were similar
between the BCG alone and BCG e oral MA groups; median fre-
quency 0.03e0.04% (Figure 4(B)). The BCG e oral MA group had agreater frequency of IL-2þ CD4þ T cells compared to the BCG alone
group. PPD-T-speciﬁc IFNgþ, TNFaþ and IL-2þ CD8þ T cells were
detected in the spleen of the BCG alone group; IFNgþ and IL-2þ
CD8þ T cells were detected in the BCG e oral MA group
(Figure 4C). Frequencies of IFNgþ and IL-2þ CD8þ T cells were
similar between the groups at 0.02% and 0.01% respectively. Fre-
quencies of IL-4þ CD4þ T cells speciﬁc for PPD-T were measured in
the mesenteric LN (mLN) of the BCG e oral MA group at around
0.01%, a median frequency of 0% was detected in the BCG alone
group (Figure 4D). PPD-T speciﬁc IL-4þ CD4þ T cells were detected
in the spleens of the BCG e oral MA and BCG alone groups at 0.01%
and 0.03% respectively; the difference was not statistically signiﬁ-
cant. PPD-T-speciﬁc IL-10 þ CD4þ T cells were detected in the mLN
of the BCG e oral MA group and the BCG alone group at 0.01% and
0.02% respectively (Figure 4(E)). The frequency of IL-10 þ CD4þ T
cells in the spleen was comparable between the groups. Fre-
quencies of regulatory T cells in the mLN were signiﬁcantly greater
in the BCG e oral MA group compared to the BCG alone group; 13%
and 9% respectively (p ¼ 0.008; Figure 4(F)). Both groups had a
median frequency of regulatory T cells around 3% in the spleen.
3.5. Oral exposure to live MA after BCG vaccination reduces
protection against M. tb
Thirty ﬁve days after aerosol M. tb challenge, the group that
received MA 104 orally after BCG had a signiﬁcantly greater CFU
burden in the spleen compared to the BCG alone group (p ¼ <0.05
spleen). The mean CFU count in the lung of the group receiving MA
104 orally after BCG was greater compared to the group that
received BCG alone but this difference did not reach statistical
signiﬁcance. The mean Log(10) CFU counts in the naïve group was
5.62 lung; 4.36 spleen, in the BCG alone group 4.92 lung; 2.34
spleen and in the group that received MA 104 after BCG 5.1 lung;
3.63 spleen (Figure 5). Both the BCG alone group and the group
receiving MA 104 orally after BCG had a signiﬁcantly lower CFU
burden in the lungs compared to naïve mice and the BCG alone
group had signiﬁcantly lower CFU burden in the spleen compared
to naïve mice (p ¼ <0.0001 lungs, p ¼ <0.001 spleen BCG alone;
p ¼ <0.0001 lungs, p ¼ ns spleen BCG e oral MA;Figure 5(A) and
(B). The CFU burden in the spleen of the group receiving MA 104
orally after BCG was not signiﬁcantly different to the naïve group.
3.6. The cellular immune response during M. tb infection is altered
by oral exposure to MA after BCG vaccination
We also measured the responses of lymphocytes followingM. tb
challenge in the oral exposure model. Again, CD44 expression was
used as amarker for CD4þ and CD8þ Tcell activation. Thirteen days
after challenge, signiﬁcantly greater frequencies of activated CD4þ
T cells were detected in the lungs of the BCG alone group compared
to the naïve group; 12%e8% respectively (p < 0.01; Figure 6(A)). 16
days after challenge the frequency of activated CD4þ T cells in the
lungs was similar between the BCG alone and BCG e oral MA
groups at 30%; this was greater than the frequency in the naïve
group which was 15%, although the difference did not reach sta-
tistical signiﬁcance (Figure 6(B)). The same trend was also seen in
the pLN and spleen at day 16 (data not shown). No PPD-T-speciﬁc
cytokine responses were detected at day 13 in any of the groups
(data not shown). At day 16 IFNgþ and TNFaþ CD4þ T cells were
detected in the lungs of the BCG alone and the BCG e oral MA
groups at similar frequencies; 1.5e2% (Figure 6(C)). Median fre-
quencies of activated CD8þ T cells were greater in the lungs, pLN
and spleen of the BCG alone and BCG e oral MA groups compared
to the naïve group; however these differences were not signiﬁcant
(Figure 6(E); spleen not shown). The frequency of IFNgþ CD8þ T
Figure 5. Burden of M. tb CFU in the lungs and spleens 35 days after challenge Groups in the challenge included naïve mice, BCG vaccinated mice (BCG) and BCG vaccinated
followed by oral MA 104 exposure mice (BCG þMA 104). Data is Log (10) of the CFU count of the whole organ. Each data point represents one mouse and the mean is displayed. A
One-way ANOVA with Bonferroni post test was used to determine statistical signiﬁcance; the p value for each comparison is displayed. Colony forming units (CFU), 6 months since
BCG (6 m).
Figure 6. Cellular response toM. tb infection 16 days after challenge Thirteen and sixteen days afterM. tb challenge cells were isolated from lungs and pulmonary lymph nodes (LN)
of naïve mice, BCG vaccinated mice (BCG) and BCG vaccinated mice followed by oral MA 104 exposure (BM oral). Cells were stimulated with PPD-T and then stained for analysis by
ﬂow cytometry. (A and B) CD44 þ CD4þ T cells in the lung at day 13 and 16 after infection, (C) IFNg, TNFa and IL-2 production from CD4þ T cells in the lung at day 16, (D) IL-
17 þ CD4þ T cells in the lung and LN at day 16, (E) CD44 þ CD8þ T cells in the lung and LN at day 16, (F) IFNg, TNFa and IL-2 production from CD8þ T cells in the LN at day 16, (G) IL-
4þ CD4þ T cells in the lung and LN at day 16, (H) expression of CD25, FoxP3 and CD39 on CD4þ T cells from the lung and LN at day 16. Cytokine responses are antigen-speciﬁc;
media control well values are subtracted. Regulatory T cell frequency is not antigen-speciﬁc. Each data point represents one mouse and the median is displayed. The One-way
ANOVA KruskaleWallis with Dunns post test was used to determine statistical signiﬁcance; the p value is displayed where signiﬁcance was calculated.
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quencies 0.18e0.2% (Figure 6(F)). TNFaþ CD8þ T cells were detec-
ted in the BCG e oral MA group but not the BCG alone or naïve
groups. Only a low level CD8þ T cell response was detected in the
lungs at this time (data not shown).
A high frequency of IL-17 þ CD4þ T cells was detected in the
lungs of the BCGe oral MA group; 6.5% (Figure 6(D)). In the lungs of
the BCG alone group 4% of CD4þ Tcells were IL-17þ; this was lower
than recorded in the BCG e oral MA group however the difference
was not statistically signiﬁcant. A similar trend was seen in the pLN
but at lower frequencies. A greater frequency of IL-4þ CD4þ T cells
was detected in the lungs of the BCG e oral MA group compared to
the BCG alone group; 0.8% and 0.2% respectively; the differencewas
not statistically signiﬁcant between these groups but was against
naive mice (p < 0.01; Figure 6(G)). No IL-4þ CD4þ T cell response
was recorded in the pLN. Regulatory T cell frequencies were similar
between the 3 groups in the lungs (Figure 6(H)). In the pLN a similar
frequency was recorded in the BCG e oral MA group and BCG alone
groups at around 5.5%. Fewer regulatory T cells were recorded in
the naïve group; this difference was not signiﬁcant. There was no
difference in the IL-10 response between the groups (data not
shown).
4. Discussion
Thirty-ﬁve days after M. tb challenge, mice exposed to killed
MA-IP after BCG vaccination had a signiﬁcantly lower CFU burden
in lungs compared tomice receiving BCG alone, demonstrating that
exposure to killedMA by the IP route after BCG can increase efﬁcacy
of BCG vaccination. Early inﬁltration of T helper 1 and T helper 17
responses into the lungs during M. tb infection were associated
with increased protection. Mice that had been exposed to live MA
orally after BCG had a higher burden of M. tb in the lungs and
spleens compared to mice that received BCG alone, demonstrating
that exposure to live MA by the oral route after BCG reduced the
efﬁcacy of BCG vaccination. Th2 responses in the lungs duringM. tb
infectionwere associatedwith reduced protection. There have been
previous reports of NTM exposure enhancing immunogenicity and
protection against M. tb challenge in comparison to BCG alone;
Edwards et al. showed protection was enhanced byMycobacterium
intracellulare exposure after BCG vaccination in a guinea pig study
and Howard et al. reported enhanced immunogenicity in calves
sensitised with MA prior to BCG vaccination compared to calves
which received only BCG [29,38]. The observation that oral expo-
sure to live MA reduced the efﬁcacy of BCG vaccination is in line
with data reported by Flaherty et al. (in the study from which the
model was replicated) [39]. Others have reported similar reductive
effects on BCG efﬁcacy in animal models, as discussed previously
[24,27,34].
At day 13 after M. tb infection mice that had been exposed to
killed MA-IP after BCG had higher frequencies of Th1 and Th17
subsets in the lungs compared to the BCG alone mice. Prior to
challenge it was observed that repeated doses of killed MA-IP had
increased the magnitude of IFNg, TNFa and IL-2 producing CD4þ T
cells and the ability of these cells to produce more than one of these
cytokines. A polyfunctional Th1 proﬁle has been linked to improved
vaccine efﬁcacy against M. tb in mice [41]. The enhanced Th17 and
Th1 responses seen in the lungs of the killed MA-exposed mice
duringM. tb infectionwas likely due to the enhanced frequencies of
these subsets observed pre-infection. This may have contributed to
the increased protection observed in this group compared to the
BCG alonemice; an early Th17 response in the lung has been shown
to aid protection by induction of chemokines in the lungs that
promote chemotaxis of Th1 cells to this site early in infection [42].
Prior to M. tb infection we observed a CD8þ T cell response in thekilled-MA exposed mice but not in the BCG alone mice, this may
have been due to a wane in the response in the BCG alone mice
given vaccination was 12 months previously and they received no
further mycobacterial exposure. Frequencies of CD8þ T cells were
signiﬁcantly greater in the LN of the killed MA-exposed mice 13
days after infection compared to the BCG alone mice and we also
observed a greater frequency in the lungs at day 16 after infection.
Mittrucker et al. correlated an early accumulation of CD8þ T cells to
vaccine-mediated protection in M. tb infection; this study suggests
that the enhanced frequency of this subset in our model may have
played a role in controlling M. tb [43].
Unlike the killed IP model, we did not see an enhanced Th1
response before M. tb infection in mice exposed to live MA-orally
compared to the BCG alone mice. Instead, we observed a signiﬁ-
cant increase in the frequency of Tregs in the mesenteric lymph
nodes. The intestinal immune system is highly specialised to deal
with constant antigen exposure from intestinal ﬂora and food
antigens and induces a tolerising environment to prevent
inﬂammation against these common antigens [44,45]. Studies of
oral MA infection have reported low levels of pro-inﬂammatory
cytokines and instead a local and systemic IL-10 response
induced during infection [46,47]. Furthermore, in vitro analysis has
shown that intestinal macrophages infected with MA secreted
lower levels of TNFa compared to their systemic counterparts;
blocking IL-10 and TGFb allowed these macrophages to kill intra-
cellular bacteria [48]. DuringM. tb infectionwe observed a delayed
inﬁltration of activated CD4þ T cells to the lungs of the mice that
received oral MA after BCG compared to mice that received BCG
alone. It is possible the delayed CD4þ T cell inﬁltration in the live
MA-oral model may be linked to the reduction in vaccine efﬁcacy,
this is in agreement with the association of an early Th1 and Th17
pulmonary response and increased protection that we observed in
the killed MA-IP model. It is important to note that no cytokine
production from CD4þ T cells was detected in the lungs of the BCG
alone group at day 13, as a result the subset of CD44þ CD4þ T cells
could not be deﬁned and their functional capability at this time
point remains questionable. Prior toM. tb challenge we observed a
signiﬁcantly enhanced Treg response in the mesenteric LN of the
live MA exposed group, however this group had a similar fre-
quency of Tregs in the pulmonary LN during M. tb infection
compared to the BCG alone group. Given the similar frequency of
Tregs between the groups during infection it is unlikely that reg-
ulatory responses were accountable for the delay in activated T
cells accumulating in the lungs of MA-exposed mice during M. tb
infection. By day 16 after infection both vaccinated groups had
comparable frequencies of Th1 in the lungs and a similar response
in all three groups was detected in the LN. A signiﬁcantly greater
frequency of Th17 cells was detected in the lungs of the MA-
exposed group. These results show that by day 16 Th1 and Th17
immune responses were equivalent if not enhanced in the live
MA-exposed group and suggests that the mechanism by which
vaccine efﬁcacy is reduced is not likely to be through a reduction of
these cell subsets.
The appearance of Th2 immune responses duringM. tb infection
in the lungs of mice exposed orally to live MA is potentially
important in terms of understanding the mechanisms behind the
varying effect of NTM exposure on BCG efﬁcacy. Th2 responses
were also detected in mice exposed to killed MA-IP but the fre-
quency of IL-4þ CD4þ T cells in killed MA-IP mice was lower
compared to the orally exposed mice. It may be that the increased
frequencies of IL-4þ CD4þ T cells in the lungs of the live MA-oral
mice during M. tb infection has a negative impact on infection
control. IL-4 can inhibit inducible nitrous oxide synthase activity,
which is a key mechanism in the control of M. tb in macrophages
[49]. IL-4 knockout mice were shown not to be better at controlling
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suggests that a normal level of Th2 response is not detrimental in
M. tb infection [50]. However, BALB/C mice mount a Th2 skewed
immune response and are more susceptible to M. tb than C57BL/6
mice [51]. IL-4 is produced in the late stages of infection in BALB/C
mice and is linked to an increase in pathology in this strain [51,52].
These reports may imply that a higher ratio of Th2/Th1 in long-
term infection is pathological. In the live MA-oral exposure model
it is possible that the Th2 response may have begun to expand by
day 35 after infection, which is why there was a moderate effect on
the level of BCG efﬁcacy at this time point. In the report published
by Flaherty et al., M. tb infection was followed-up to day 120 and
showed lower BCG efﬁcacy in the MA-exposed group at this time
point compared to the 35 day time point [39]. It may be that at this
later stage Th2 responses have further expanded in the MA-
exposed group compared to the BCG alone group. This hypothesis
remains to be tested but is a plausible explanation for the reduced
efﬁcacy observed in mice exposed to live MA-orally after BCG.
Functional studies could help delineate the importance of the Th2
response in lowering BCG mediated protection in the oral model.
Further studies are also required to demonstrate whether the
increased Th1 and Th17 inﬁltrate observed in the killed MA-IP
model is the mechanism by which efﬁcacy is enhanced in this
model.
Our study has focussed on comparing the immune response
induced in a model of NTM exposure that enhances BCG efﬁcacy to
that induced in a model of NTM exposure that compromises BCG
efﬁcacy with the view to understand the immunological mecha-
nisms that mediate these effects. The main limitation in our study
design is that the models were not evaluated with the same strain
of MA and that both live and dead bacteria were not tested in the
same model. This has prevented us from delineating which pa-
rameters mediate the differential effects on vaccine efﬁcacy;
whether it is viability of the bacteria, the route of exposure or the
strain of MA employed. However, the results have demonstrated
that a model of NTM exposure that induces Th2 type responses and
a regulatory response is associated with reduced vaccine efﬁcacy.
Further work can lead to determining which parameters are most
important in inducing these types of responses and reduced vac-
cine efﬁcacy. Live MA 724 could be assessed in the systemic model
to evaluate the importance of MA viability in enhancing protective
immunity. In previous studies the immune response induced by
administering live MA 724 by the IP route was compared to the
killed preparation. We found the Th1 and Treg response to be
similar between the two, which suggests that viability may not
affect the ability of MA exposure to enhance BCG efﬁcacy via the IP
route (Supplementary Figure 4). The administration of live MA
orally induced a large Treg response, which was not seenwhen live
MA was given IP. We conclude that the oral route of exposure in-
duces this regulatory phenotype implicating route as a contributing
factor to the reduced efﬁcacy observed in theMA-oral model. These
experiments are not directly comparable as no prior BCG vaccina-
tion was given when live MA IP was tested, although we do not
think prior BCG would have changed the immune response we
measured. Whether or not viability is important in reducing vac-
cine efﬁcacy in the MA-oral model is an important further experi-
ment. We suspect MA may need to be living to exert these
immunological effects. Sangari et al. report that MA 104 invades the
intestinal mucosa through enterocytes and enables it to dissemi-
nate and infect intestinal macrophages, which is likely to be an
important step in modulating the immune response against the
mycobacterium [53]. Both invasion and intracellular survival within
macrophages are active processes and require the bacteria to be
alive. An additional parameter to evaluate would be the difference
in immunogenicity between the two strains used in the models.Different strains of MA and indeed other species of mycobacteria
stimulate different arms of the immune response to variable
magnitudes; therefore we cannot predict that the outcome of
either of these exposure models will be replicated if a different
NTM isolate is used. Non-pathogenic species of mycobacteria have
uncapped lipoarabinomannan (LAM), which can bind to toll-like
receptor (TLR) 2 and CD14 to induce phagocyte activation and in-
duction of pro-inﬂammatory IL-6 and IL-1b [54]. Mannose capping
of LAM avoids binding to TLR2 and instead can bind DC-SIGN and
induce IL-10 production from dendritic cells (DC) [55]. Different
species of MA have variable levels of mannose capping which may
in part explainwhy different NTM isolates activate different arms of
the immune response. MA 104 may inﬂuence the regulatory
phenotype we observed in the MA-oral model simply by having a
high level of mannose capped LAM. Killed MA 724-IP enhanced
IFNg production from CD4þ T cells and CD8þ T cells whilst having
little effect on the regulatory response which may suggest that MA
724 has a low level of mannose capped LAM. Employing MA 724 in
the oral model and MA 104 in the IP model would clarify the
importance of strain in the outcomes we observed.
What restricted us from performing the evaluations above was
the timeframes required to complete these models. We know that
repeated doses of MA after BCG induce a stronger effect on the
immune response than a single dose but it may be possible to
manipulate the models by reducing the number of doses and time
between doses, thus reducing the timeframe required to complete
themodels to enable faster evaluation of the outstanding questions.
Exposure to NTM is likely to be an important factor in the
reduction of BCG efﬁcacy in tropical regions. This study shows that
exposure to NTM can generate diverse effects on BCG mediated
protection depending on the model of exposure that is used.
Humans are likely to be exposed to different NTM species, via
different routes of infection and with both live and dead bacteria.
There is a need to determine which exposures are detrimental to
BCG efﬁcacy, and to deﬁne the immunological mechanisms that
modify the protective response conferred by BCG. Without under-
standing the reasons behind the variable efﬁcacy of BCG, we cannot
predict whether the efﬁcacy of a novel TB vaccine candidate will be
compromised in the same way. A reproducible model of NTM
exposure is necessary to evaluate novel TB vaccine candidates
during their development. More research is required in this ﬁeld to
ensure we have an efﬁcacious TB vaccine for all populations.
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